Şunu aradınız:: ic95(2) (Fransızca - İngilizce)

(ic95 %)
(95% ci)

rr (ic95 %)
< 0.0001 / < 0.0001

7%, ic95% -2%; 17%).
at the end of the maintenance treatment an improvement of at least 30% was seen in 60% of the subjects receiving rotigotine, 67% of the subjects receiving pramipexole and 35% of the subjects receiving placebo (difference rotigotine versus placebo 25%; ci95% 13%; 36%, difference pramipexole versus placebo 32% ci95% 21%; 43%, difference pramipexole versus rotigotine 7%; ci95% -2%; 17%). the mean reduction in the “ off” time was 2.5 hours in the rotigotine arm, 2.8 hours in the pramipexole arm and 0.9 hours in the placebo arm.

différence [ic95 ]
difference [95% ci]

placebo (ic95%), p
tropos

1,032(semaines)[ ic95%:
1.032 [ 95% ci:

ic95% 0,93%; 7,97%
4.5% (0 h 35 min) ci95% 0.93%, 7.97%

orr (réponses partielles uniquement) (ic95 %)
orr (partial responses only) (95% ci)

l’ ic95% de la différence été de 42,2-85,7.
the 95% ci of the difference was 42.2-85.7.

ic95 % 45 min, 1 h 56 min
ci95% 45 min, 1 h 56

réduction par rapport au placebo (ic95%)
change relative to placebo (ci95%)

n/n % ic95 % n/n % ic95
n/n % 95% ci n/n % 95% ci

délai médian jusqu’ à événement (jours) (ic95%)
median time to event (days)

risque relatif : 1,032 [ic95% :
hazard ratio: 1.032

réduction du risque relatif vs. placebo (ic95%), p
relative risk reduction vs. placebo (95%ci), p value

52,8­65,9) dans le bras at versus 46,5% (ic95%:
52.8 -65.9) in at arm versus 46.5% (95% ci:

la durée médiane de la survie globale était de 703 jours (ic95%:
median overall survival time was 703 days (95% ci:

groupe # repondeurs / # randomises hazard ratio (ic95%)
group # responders / # randomized hazard ratio (95% ci)

(8,3%) ic95% 45 min, 1 h 56 min etude ii:
(8.3%) ci95% 45 min, 1 h 56 min study ii:

a la fin du traitement d'entretien, on a constaté une amélioration d'au moins 30% chez 60% des sujets traités à la rotigotine, 67% des sujets traités au pramipexole et 35% des sujets recevant un placebo (différence rotigotine versus placebo:25%, ic95% 13%; 36%, différence pramipexole versus placebo:32%, ic95% 21%; 43%, différence pramipexole versus rotigotine:7%, ic95% -2%; 17%) .
at the end of the maintenance treatment an improvement of at least 30% was seen in 60% of the subjects receiving rotigotine, 67% of the subjects receiving pramipexole and 35% of the subjects receiving placebo (difference rotigotine versus placebo 25%; ci95% 13%; 36%, difference pramipexole versus placebo 32% ci95% 21%; 43%, difference pramipexole versus rotigotine 7%; ci95% -2%; 17%) . the mean reduction in the " off " time was 2.5 hours in the rotigotine arm, 2.8 hours in the pramipexole arm and 0.9 hours in the placebo arm.